Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

PRIMARY OBJECTIVES:

I. To determine if 68Ga-DOTATOC (gallium Ga 68-edotreotide) PET when combined with magnetic
resonance imaging (MRI) will differentiate embryonal tumors such as medulloblastoma and
supratentorial primitive neuroectodermal tumor (PNET) from the low and high grade gliomas.

II. To determine if 68Ga-DOTATOC PET will aid in the identification of residual tumor post
operatively in those patients who were 68Ga-DOTATOC PET positive prior to surgery.

OUTLINE:

Patients undergo gallium Ga 68-edotreotide PET/CT at baseline and 1-30 days after surgery.

Inclusion Criteria:

- Patients presenting with brain tumors will be eligible for this study

- Eligible subjects must be able and willing to undergo the procedures of the study

- Electronic version of pre-surgery MRI must be available for co-registration purposes

- Fresh frozen tumor, and/or paraffin block of biopsy or resected tumor is recommended,
but not required to determine expression of somatostatin receptors in tumor by
immunohistochemistry and/or quantitative polymerase chain reaction (qPCR)

Exclusion Criteria:

- Women who are pregnant or breastfeeding

- Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal
fragments or foreign objects in the eyes, skin of body that would preclude obtaining
an MRI as part of the initial study evaluation

- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons

- Presence of any additional medical condition such as inter-current illness, or other
extenuating circumstance that, in the opinion of the investigator, may significantly
interfere with study compliance